UY37975A - Nuevos antigenos de proteinas de la envoltura del virus de la inmunodeficiencia humana (vih) expresados en celulas de mamiferos - Google Patents

Nuevos antigenos de proteinas de la envoltura del virus de la inmunodeficiencia humana (vih) expresados en celulas de mamiferos

Info

Publication number
UY37975A
UY37975A UY0001037975A UY37975A UY37975A UY 37975 A UY37975 A UY 37975A UY 0001037975 A UY0001037975 A UY 0001037975A UY 37975 A UY37975 A UY 37975A UY 37975 A UY37975 A UY 37975A
Authority
UY
Uruguay
Prior art keywords
hiv
expressed
cells
polypeptides
mammals
Prior art date
Application number
UY0001037975A
Other languages
English (en)
Inventor
Witt Jody Melton
Son Sodany
Mark Baumeister
Jody Berry
Original Assignee
Grifols Diagnostic Solutions Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grifols Diagnostic Solutions Inc filed Critical Grifols Diagnostic Solutions Inc
Publication of UY37975A publication Critical patent/UY37975A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)

Abstract

Diversas realizaciones de la presente invención se refieren a polipéptidos que comprenden 1-10 o más epítopos de la proteína de la envoltura del VIH y una proteína de fusión, en los que el polipéptido carece del dominio transmembrana de la proteína gp41 del VIH. Dichos polipéptidos se pueden expresar en células de mamífero, tales como células humanas, para producir, por ejemplo, polipéptidos que son útiles en el desarrollo de nuevos anticuerpos anti-VIH. Los polipéptidos que se describen en la presente memoria descriptiva y los nuevos anticuerpos desarrollados a partir de los mismos son útiles generalmente para el diagnóstico médico y también pueden ser útiles en el tratamiento profiláctico y terapéutico del VIH.
UY0001037975A 2017-11-17 2018-11-16 Nuevos antigenos de proteinas de la envoltura del virus de la inmunodeficiencia humana (vih) expresados en celulas de mamiferos UY37975A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762588085P 2017-11-17 2017-11-17

Publications (1)

Publication Number Publication Date
UY37975A true UY37975A (es) 2019-02-28

Family

ID=64477227

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037975A UY37975A (es) 2017-11-17 2018-11-16 Nuevos antigenos de proteinas de la envoltura del virus de la inmunodeficiencia humana (vih) expresados en celulas de mamiferos

Country Status (12)

Country Link
US (1) US20210179668A1 (es)
EP (2) EP4375668A3 (es)
JP (3) JP2020503839A (es)
KR (3) KR20210097833A (es)
CN (1) CN110049995A (es)
AR (1) AR114560A1 (es)
AU (2) AU2018366480C1 (es)
CA (1) CA3077340A1 (es)
PL (1) PL3504225T3 (es)
TW (2) TW201922800A (es)
UY (1) UY37975A (es)
WO (1) WO2019097466A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3031923A1 (en) * 2014-12-11 2016-06-15 Institut Pasteur Lentiviral vector-based japanese encephalitis immunogenic composition
CA3077340A1 (en) 2017-11-17 2019-05-23 Grifols Diagnostic Solutions Inc. Novel mammalian expressed human immunodeficiency virus envelope protein antigens
CN113773384B (zh) * 2020-06-19 2023-07-04 西南大学 用于直接检测蚕丝丝胶蛋白的多肽抗体及制备方法及应用
CN115586338A (zh) * 2022-09-20 2023-01-10 杭州赛基生物科技有限公司 用于检测可溶性细胞因子受体的试剂盒及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248574B1 (en) * 1989-12-13 2001-06-19 Avigdor Shaffermann Polypeptides selectively reactive with antibodies against human immunodeficiency virus and vaccines comprising the polypeptides
FR2676071B1 (fr) * 1991-05-02 1994-11-18 Transgene Sa Nouveau variant gp160 non-clivable, soluble, de forme hybride.
ES2194015T3 (es) * 1992-09-30 2003-11-16 Scripps Research Inst Anticuerpos monoclonales humanos neutralizantes del virus de inmunodeficiencia humana.
US5541087A (en) * 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
EP2374811A1 (en) * 2002-07-23 2011-10-12 Duke University IgG Fc/HIV-gp120/c3d fusion protein
JP2011502521A (ja) * 2007-11-12 2011-01-27 ザ ヘンリー エム． ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド Ｈｉｖ−１外被糖タンパク質オリゴマー及び使用方法
WO2009137632A2 (en) * 2008-05-06 2009-11-12 Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Hiv immunogen and method of making and using same
EP3486255A3 (en) * 2013-03-13 2019-11-13 Ibentrus Inc. Protein in which electrical interaction is introduced within hydrophobic interaction site and preparation method therefor
WO2016028917A2 (en) * 2014-08-20 2016-02-25 University Of Maryland, Baltimore Stable immunogen based on inner domain of hiv-1 gp120 for inducing immunity against hiv
PT3390430T (pt) * 2015-12-15 2019-11-20 Janssen Vaccines & Prevention Bv Antígenos, vetores, composições para o vírus da imunodeficiência humana e métodos da sua utilização
CA3077340A1 (en) 2017-11-17 2019-05-23 Grifols Diagnostic Solutions Inc. Novel mammalian expressed human immunodeficiency virus envelope protein antigens

Also Published As

Publication number Publication date
TW201922800A (zh) 2019-06-16
US20210179668A1 (en) 2021-06-17
AR114560A1 (es) 2020-09-23
EP4375668A2 (en) 2024-05-29
KR20230019227A (ko) 2023-02-07
KR20190057276A (ko) 2019-05-28
AU2018366480A1 (en) 2020-04-23
PL3504225T3 (pl) 2024-07-22
EP4375668A3 (en) 2024-08-14
CA3077340A1 (en) 2019-05-23
AU2023229556A1 (en) 2023-09-28
JP2022022308A (ja) 2022-02-03
KR20210097833A (ko) 2021-08-09
EP3504225A1 (en) 2019-07-03
EP3504225B1 (en) 2024-04-24
AU2018366480B2 (en) 2023-06-15
WO2019097466A1 (en) 2019-05-23
TW202417468A (zh) 2024-05-01
AU2018366480C1 (en) 2024-02-01
CN110049995A (zh) 2019-07-23
JP2023057154A (ja) 2023-04-20
JP2020503839A (ja) 2020-02-06

Similar Documents

Publication Publication Date Title
UY37975A (es) Nuevos antigenos de proteinas de la envoltura del virus de la inmunodeficiencia humana (vih) expresados en celulas de mamiferos
CL2017002199A1 (es) Vectores retrovirales a lentivirales
CL2019000067A1 (es) Anticuerpos nuevos que se unen específicamente a los epítopos del virus del zika y usos de los mismos.
MD3672614T2 (ro) Vezicule extracelulare modificate și utilizări ale acestora
PE20200152A1 (es) Receptores de union a antigeno mejorados
AR106144A1 (es) Un conjugado de proteína que comprende polipéptidos fisiológicos y una región fc inmunoglobulina
CY1121323T1 (el) Αντισωματα εξουδετερωσης του ιου ανθρωπινης ανοσοανεπαρκειας (hiv)
AR109528A1 (es) Mutaciones estabilizantes de trímeros de proteínas de la envoltura del vih
PE20081686A1 (es) Proteinas de fusion que comprenden un antigeno prame (dage)
CU20180062A7 (es) Anticuerpos neutralizadores del virus de inmunodeficiencia humana
CL2013003634A1 (es) Complejo que comprende una proteina de fusion que comprende, un peptido viral, peptido conector, microglobulina beta 2 , peptido conector, dominios extracelulares alfa 1, 2 y 3 de mhc de clase i y un tercer peptido conector; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso
EA202190906A1 (ru) Рекомбинантное получение препаратов пептидов коллагена и их применение
BR112016022819A2 (pt) uso de um método, método para a produção de um anticorpo com reatividade cruzada para humano e cinomolgo e anticorpo com reatividade cruzada para humano e cinomolgo
AR102522A1 (es) Variantes de región fc con propiedades modificadas de unión a fcrn y proteína a
JP2016519933A5 (es)
PE20040554A1 (es) Vacunas que comprenden proteinas de fusion
BR112015019066A2 (pt) Anticorpos humanos para proteína f do vírus respiratório sincicial e métodos de uso dos mesmos
EP2926830A3 (en) Human immunodeficiency virus (HIV)-neutralizing antibodies
CO2019014677A2 (es) Vectores de poxvirus que codifican antígenos del virus de inmunodeficiencia humana (vih), y métodos de uso de los mismos
WO2016073595A8 (en) T cells and dendritic cells for polyomavirus therapy
PE20190966A1 (es) Factor viii direccionado a los globulos rojos y metodo para su uso
EA201892233A1 (ru) Композиции и способы, связанные с иммуногенами вич-1
EA201692279A1 (ru) Способ уменьшения иммуногенности белка и пептида
EA201790680A1 (ru) Вакцины против вируса иммунодефицита человека (вич), содержащие один или более эписенсусных (episensus) для популяции антигенов
CL2016002142A1 (es) Proteínas de fusión tatk-cdkl5, composiciones, formulaciones y uso de estas